Paclitaxel-HA Intravesical Conjugate for BCG-Refractory NMIBC
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for non-muscle invasive bladder cancer (NMIBC), particularly bladder carcinoma in situ (CIS), are costly due to high recurrence rates and require intensive surveillance, and immunotherapy with Bacillus Calmette-Guérin (BCG) is poorly tolerated and ineffective for some patients, necessitating radical cystectomy, while paclitaxel administration causes systemic toxicity and hypersensitivity.
Innovation Solution
A paclitaxel prodrug conjugated with hyaluronic acid through a 4-bromobutyric acid spacer is administered via intravesical instillation, either as a single weekly dose of 600 mg for 12 weeks or two weekly doses of 600 mg each for 6 weeks, to target tumor cells specifically and reduce systemic absorption.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If paclitaxel is administered systemically to treat bladder cancer, then tumor cells are targeted, but systemic toxicity and hypersensitivity occur
Solution Approach 1:
The patent applies local quality by transforming paclitaxel into a prodrug conjugate with hyaluronic acid that exhibits selective accumulation in bladder tumor tissue through intravesical instillation. The conjugate is designed to be retained locally in the bladder while being selectively taken up by tumor cells, thereby achieving localized treatment effect with minimal systemic exposure and reduced toxicity
Solution Approach 2:
The patent uses an intermediary approach by creating a paclitaxel-prodrug conjugate with hyaluronic acid that serves as a mediator between the chemotherapeutic agent and the target tissue. This conjugate enables selective delivery of paclitaxel to bladder tumor cells while reducing direct systemic contact with the parent drug, thereby minimizing hypersensitivity and systemic side effects
2Reliability
If immunotherapy with BCG is used to treat NMIBC, then recurrence prevention is improved, but treatment intolerance and ineffectiveness in some patients occur
Solution Approach 1:
The patent applies parameter changes by switching from immunotherapy (BCG) to chemotherapy (paclitaxel prodrug) as the treatment modality. This parameter change allows treatment of patients who are intolerant or refractory to BCG, providing an alternative mechanism of action while maintaining effectiveness in preventing recurrence through selective tumor cell killing
3Reliability
If intensive surveillance and repeated treatments are implemented for NMIBC, then recurrence management is improved, but treatment cost increases
Solution Approach 1:
The patent extracts the essential therapeutic function from complex, costly treatment regimens by using a single prodrug formulation that combines the advantages of localized delivery, selective tumor targeting, and sustained release. This extraction simplifies the treatment approach, potentially reducing the need for intensive surveillance and repeated treatments, thereby lowering overall treatment costs
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The treatment effectively eliminates CIS in 75% of patients refractory to BCG, avoiding radical cystectomy and minimizing systemic toxicity and adverse events, with no significant drug absorption detected.
Implementation Method 1
administered by intravesical instillation
Data Source
AI summary
A pharmaceutical composition is described, essentially consisting of the paclitaxel prodrug associated with pharmacologically acceptable diluents/excipients, for use in the treatment of non-muscle invasive bladder cancer (NMIBC) by means of intravesical instillations according to a single weekly dose of 600 mg of said prodrug, or two weekly doses equal to a total of 1,200 mg, for 12 or 6 consecutive weeks of treatment. The paclitaxel prodrug used was prepared according to an indirect synthesis process between molecules of hyaluronic acid (HA) and paclitaxel by introducing a spacer (4-bromobutyric acid) between the hyaluronic acid and chemotherapeutic agent.